Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 5, 2009, Pages 554-561

  Brown, Todd T ^a   McComsey, Grace A ^b   King, Martin S ^c   Qaqish, Roula B ^c   Bernstein, Barry M ^c   Da Silva, Barbara A ^c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

Bone mineral density; DXA; Efavirenz; Lopinavir ritonavir

Indexed keywords

EFAVIRENZ; GLUCOSE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BODY FAT DISTRIBUTION; BODY WEIGHT; BONE DENSITY; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OPEN STUDY; OSTEOPOROSIS; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; STATISTICAL ANALYSIS; TREATMENT DURATION; VIRUS LOAD;

ABSORPTIOMETRY, PHOTON; ADULT; ANTI-HIV AGENTS; BENZOXAZINES; BONE DENSITY; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION MEDIATORS; LAMIVUDINE; MALE; MIDDLE AGED; OSTEOPOROSIS; PROSPECTIVE STUDIES; PYRIMIDINONES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RISK FACTORS; RITONAVIR; ZIDOVUDINE;

EID: 68449094355     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181adce44     Document Type: Article

References (42)

1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20:2165-2174.
2. Klein RS, Lo Y, Santoro N, et al. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis. 2005;41:1794-1803.
3. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003;37:292-298.
4. Bolland MJ, Grey AB, Gamble GD, et al. Review #: low body weight mediates the relationship between HIV infection and low bone mineral density: a meta-analysis. J Clin Endocrinol Metab. 2007;92:4522-4528.
5. Zenilman JM, Hook EW III, Shepherd M, et al. Alcohol and other substance use in STD clinic patients: relationships with STDs and prevalent HIV infection. Sex Transm Dis. 1994;21:220-225.
6. Kwan TS, Padrines M, Theoleyre S, et al. RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev. 2004;15:49-60.
7. Fakruddin JM, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol. 2005;150:67-78.
8. Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003;278:48251-48258.
9. Pan G, Kilby M, McDonald JM. Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors. AIDS Res Hum Retroviruses. 2006;22:1131-1141.
10. Pan G, Wu X, McKenna MA, et al. AZTenhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses. 2004;20:608-620.
11. Castillo AB, Tarantal AF, Watnik MR, et al. Tenofovir treatment at 30 mg/kg/day can inhibit cortical bone mineralization in growing rhesus monkeys (Macaca mulatta). J Orthop Res. 2002;20:1185-1189.
12. Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem. 2002;277:19247-19250.
13. Wang MW, Wei S, Faccio R, et al. The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest. 2004;114:206-213.
14. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA. 2004;292:191-201.
15. Bonnet E, Mabile L, Ruidavets J-B, et al. Important changes in bone metabolism soon after commencing HAART. Presented at: 9th Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; July 19-21, 2007; Sydney, Australia.
16. Duvivier C, Kolta S, Assoumou L, et al. First line PI-containing regimens cause a greater decrease in bone mineral density compared to NNRTIcontaining regimens in HIV-1 infected patients: a substudy of HIPPOCAMPEANRS 121 trial [967]. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-8, 2008; Boston, MA.
17. Tebas P, Umbleja T, Dube MP, et al. Initiation of ART is associated with bone loss independent of the specific ART regimen: results of ACTG A5005s. Presented at: 14th Conference on Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.
18. Cameron DW, da Silva B, Arribas JR, et al. Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/r monotherapy compared with EFV + ZDV/3TC [44LB]. Presented at: 14th Conference of Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.
19. Cameron DW, da Silva B, Arribas JR, et al. A two-year randomised controlled clinical trial in antiretroviral-naive patients using lopinavir/ritonavir monotherapy after initial induction treatment compared to an efavirenz 3-drug regimen: 96 week results (Study M03-613) [THLB0201]. Presented at: XVIth International AIDS Conference; August 13-18, 2006; Toronto, Ontario.
20. Campo RE, da Silva B, Gathe J, et al. Predictors of loss of virologic response in subjects who deintensified to lopinavir/ritonavir monotherapy after acheiving plasma HIV-1 RNA < 50 copies/mL on lopinavir/ritonavir plus zidovudine/lamivudine. Presented at: 14th Conference of Retroviruses and Opportunistic Infections; February 25-28, 2007; Los Angeles, CA.
21. Mynarcik DC, McNurlan MA, Steigbigel RT, et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr. 2000;25:312-321.
22. Recker R, Lappe J, Davies K, et al. Characterization of perimenopausal bone loss: a prospective study. J Bone Miner Res. 2000;15:1965-1973.
23. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
24. Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36:482-490.
25. Nolan D, Upton R, McKinnon E, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15:1275-1280.
26. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006;91:2938-2945.
27. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res. 2000;47:121-129.
28. Tebas P, Powderly WG, Claxton S, et al. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy. AIDS. 2000;14:F63-F67.
29. Rivas P, Gorgolas M, Garcia-Delgado R, et al. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med. 2008;9:89-95.
30. Martin A, Smith DE, Carr A, et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS. 2004;18:1029-1036.
31. Ding C, Parameswaran V, Udayan R, et al. Circulating levels of inflammatory markers predict change in bone mineral density and resorption in older adults: a longitudinal study. J Clin Endocrinol Metab. 2008;93:1952-1958.
32. Aukrust P, Haug CJ, Ueland T, et al. Decreased bone formative and enhanced resorptive markers in human immunodeficiency virus infection: indication of normalization of the bone-remodeling process during highly active antiretroviral therapy. J Clin Endocrinol Metab. 1999;84:145-150.
33. Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev. 2008;29:155-192.
34. Warming L, Hassager C, Christiansen C. Changes in bone mineral density with age in men and women: a longitudinal study. Osteoporos Int. 2002;13:105-112.
35. Knoke JD, Barrett-Connor E. Weight loss: a determinant of hip bone loss in older men and women. The Rancho Bernardo Study. Am J Epidemiol. 2003;158:1132-1138.
36. Pothiwala P, Evans EM, Chapman-Novakofski KM. Ethnic variation in risk for osteoporosis among women: a review of biological and behavioral factors. J Womens Health (Larchmt). 2006;15:709-719.
37. Cazanave C, Dupon M, Lavignolle-Aurillac V, et al. Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS. 2008;22:395-402.
38. Madeddu G, Spanu A, Solinas P, et al. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2004;48:39-48.
39. Schwartz AV, Sellmeyer DE, Strotmeyer ES, et al. Diabetes and bone loss at the hip in older black and white adults. J Bone Miner Res. 2005;20:596-603.
40. Brown TT, Ruppe MD, Kassner R, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004;89:1200-1206.
41. Guaraldi G, Orlando G, Squillace N, et al. Prevalence of secondary causes of osteoporosis among HIV-infected individuals. Presented at: 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV; September 24-26, 2006; San Francisco, CA.
42. Triant VA, Brown TT, Lee H, et al. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93:3499-3504.